Trifarotene
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Trifarotene: From Acne Vulgaris to Zinc, Elevated Plasma
One-Sentence Summary
Trifarotene is a topical retinoid publicly known for the treatment of acne vulgaris. The TxGNN model predicts it may be relevant to Zinc, Elevated Plasma, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne vulgaris (topical retinoid) — not present in evidence pack, based on public drug information |
| Predicted New Indication | Zinc, Elevated Plasma |
| TxGNN Prediction Score | 99.40% (rank 13,778) |
| Evidence Level | L5 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on publicly known information, trifarotene is a retinoic acid receptor gamma (RAR-γ) selective agonist used topically for acne vulgaris. Its efficacy in that original indication is well established, but no mechanistic pathway data is currently available in this evidence pack to explain a plausible link between RAR-γ agonism and elevated plasma zinc levels.
The model’s own repurposing rationale fields for this candidate are marked pending, meaning TxGNN has not yet generated an explanatory mechanistic narrative for this pairing. Without literature, clinical trial data, or MOA-based reasoning, the connection between the original and predicted indications cannot currently be substantiated beyond the raw prediction score.
It is worth noting that the second-ranked candidate, pyogenic arthritis-pyoderma gangrenosum-acne syndrome (PAPA syndrome) (score 99.32%, rank 15,213), has a more intuitive phenotypic overlap with the original indication, since acne is a defining feature of PAPA syndrome. This candidate may warrant separate evaluation even though it falls outside the scope of the rank-1 prediction covered here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No marketing authorization is currently on file for trifarotene in this dataset (0 licenses, market status: Not marketed).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/FDA label warnings and contraindications are marked as a Blocking data gap (DG001) — this prevents any formal safety review of this candidate.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature evidence (L5, model-prediction-only), the drug has no confirmed marketing status in this dataset, and safety labeling data required for even a preliminary safety screen is missing (Blocking gap DG001). There is insufficient basis to advance this prediction.
To proceed, the following is needed:
- TFDA/FDA package insert data (warnings, contraindications) — resolves DG001, required before any S1 safety screen
- Mechanism of action (MOA) data — resolves DG002, needed to assess mechanistic plausibility
- Literature or preclinical search specifically on trifarotene and zinc metabolism/homeostasis
- Confirmation of current US marketing status and license details
- Consider evaluating the rank-2 candidate (PAPA syndrome) in parallel, given its stronger phenotypic rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.